{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:57:59Z","timestamp":1791917879286,"version":"4.3.4"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"DOI":"10.1007\/s00592-024-02438-3","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T03:03:30Z","timestamp":1736132610000},"page":"303-321","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Novel antimicrobial strategies for diabetic foot infections: addressing challenges and resistance"],"prefix":"10.1007","volume":"62","author":[{"given":"Fahaad","family":"Alenazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0999-9346","authenticated-orcid":false,"given":"Mohd Shahid","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"2438_CR1","doi-asserted-by":"publisher","first-page":"1323315","DOI":"10.3389\/fendo.2023.1323315","volume":"14","author":"FWA Waibel","year":"2023","unstructured":"Waibel FWA, U\u00e7kay I, Soldevila-Boixader L et al (2023) Current knowledge of morbidities and direct costs related to diabetic foot disorders: a literature review. Front Endocrinol (Lausanne) 14:1323315. https:\/\/doi.org\/10.3389\/fendo.2023.1323315","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2438_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/antibiotics8040193","volume":"8","author":"JM Ramirez-Acu\u00f1a","year":"2019","unstructured":"Ramirez-Acu\u00f1a JM, Cardenas-Cadena SA, Marquez-Salas PA et al (2019) Diabetic Foot Ulcers: current advances in Antimicrobial therapies and emerging treatments. Antibiot (Basel) 8:193. https:\/\/doi.org\/10.3390\/antibiotics8040193","journal-title":"Antibiot (Basel)"},{"key":"2438_CR3","doi-asserted-by":"publisher","first-page":"103604","DOI":"10.1016\/j.sjbs.2023.103604","volume":"30","author":"B Ali Alghamdi","year":"2023","unstructured":"Ali Alghamdi B, Al-Johani I, Al-Shamrani JM et al (2023) Antimicrobial resistance in methicillin-resistant staphylococcus aureus. Saudi J Biol Sci 30:103604. https:\/\/doi.org\/10.1016\/j.sjbs.2023.103604","journal-title":"Saudi J Biol Sci"},{"key":"2438_CR4","doi-asserted-by":"publisher","first-page":"628","DOI":"10.3390\/antibiotics12030628","volume":"12","author":"Z Breijyeh","year":"2023","unstructured":"Breijyeh Z, Karaman R (2023) Design and synthesis of Novel Antimicrobial agents. Antibiot (Basel) 12:628. https:\/\/doi.org\/10.3390\/antibiotics12030628","journal-title":"Antibiot (Basel)"},{"key":"2438_CR5","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.3390\/microorganisms11092311","volume":"11","author":"SJ Jo","year":"2023","unstructured":"Jo SJ, Kwon J, Kim SG, Lee S-J (2023) The Biotechnological Application of bacteriophages: what to do and where to go in the Middle of the post-antibiotic era. Microorganisms 11:2311. https:\/\/doi.org\/10.3390\/microorganisms11092311","journal-title":"Microorganisms"},{"key":"2438_CR6","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1056\/NEJMra1615439","volume":"376","author":"DG Armstrong","year":"2017","unstructured":"Armstrong DG, Boulton AJM, Bus SA (2017) Diabetic Foot Ulcers and their recurrence. N Engl J Med 376:2367\u20132375. https:\/\/doi.org\/10.1056\/NEJMra1615439","journal-title":"N Engl J Med"},{"key":"2438_CR7","doi-asserted-by":"publisher","unstructured":"Sadeghpour Heravi F, Zakrzewski M, Vickery K et al (2019) Bacterial Diversity of Diabetic Foot Ulcers: Current Status and Future Prospectives. J Clin Med 8:1935. https:\/\/doi.org\/10.3390\/jcm8111935","DOI":"10.3390\/jcm8111935"},{"key":"2438_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fcimb.2014.00171","volume":"4","author":"P Speziale","year":"2014","unstructured":"Speziale P, Pietrocola G, Foster TJ, Geoghegan JA (2014) Protein-based biofilm matrices in Staphylococci. Front Cell Infect Microbiol 4:171. https:\/\/doi.org\/10.3389\/fcimb.2014.00171","journal-title":"Front Cell Infect Microbiol"},{"key":"2438_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/antibiotics12010087","volume":"12","author":"FF Tuon","year":"2023","unstructured":"Tuon FF, Suss PH, Telles JP et al (2023) Antimicrobial Treatment of Staphylococcus aureus Biofilms. Antibiot (Basel) 12:87. https:\/\/doi.org\/10.3390\/antibiotics12010087","journal-title":"Antibiot (Basel)"},{"key":"2438_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1128\/CMR.00134-14","volume":"28","author":"SYC Tong","year":"2015","unstructured":"Tong SYC, Davis JS, Eichenberger E et al (2015) Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 28:603\u2013661. https:\/\/doi.org\/10.1128\/CMR.00134-14","journal-title":"Clin Microbiol Rev"},{"key":"2438_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41579-023-00865-7","volume":"21","author":"S Brouwer","year":"2023","unstructured":"Brouwer S, Rivera-Hernandez T, Curren BF et al (2023) Pathogenesis, epidemiology and control of Group A Streptococcus infection. Nat Rev Microbiol 21:431\u2013447. https:\/\/doi.org\/10.1038\/s41579-023-00865-7","journal-title":"Nat Rev Microbiol"},{"key":"2438_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1128\/IAI.74.1.40-48.2006","volume":"74","author":"CR Starr","year":"2006","unstructured":"Starr CR, Engleberg NC (2006) Role of hyaluronidase in subcutaneous spread and growth of group a streptococcus. Infect Immun 74:40\u201348. https:\/\/doi.org\/10.1128\/IAI.74.1.40-48.2006","journal-title":"Infect Immun"},{"key":"2438_CR13","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1128\/CMR.00104-12","volume":"26","author":"AR Spaulding","year":"2013","unstructured":"Spaulding AR, Salgado-Pab\u00f3n W, Kohler PL et al (2013) Staphylococcal and streptococcal superantigen exotoxins. Clin Microbiol Rev 26:422\u2013447. https:\/\/doi.org\/10.1128\/CMR.00104-12","journal-title":"Clin Microbiol Rev"},{"key":"2438_CR14","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3390\/toxins11060332","volume":"11","author":"P Shumba","year":"2019","unstructured":"Shumba P, Mairpady Shambat S, Siemens N (2019) The role of Streptococcal and Staphylococcal exotoxins and proteases in Human Necrotizing Soft tissue infections. Toxins (Basel) 11:332. https:\/\/doi.org\/10.3390\/toxins11060332","journal-title":"Toxins (Basel)"},{"key":"2438_CR15","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/1873-3468.13872","volume":"594","author":"S Syed","year":"2020","unstructured":"Syed S, Viazmina L, Mager R et al (2020) Streptococci and the complement system: interplay during infection, inflammation and autoimmunity. FEBS Lett 594:2570\u20132585. https:\/\/doi.org\/10.1002\/1873-3468.13872","journal-title":"FEBS Lett"},{"key":"2438_CR16","doi-asserted-by":"publisher","first-page":"e26668","DOI":"10.1016\/j.heliyon.2024.e26668","volume":"10","author":"C Hazare","year":"2024","unstructured":"Hazare C, Bhagwat P, Singh S, Pillai S (2024) Diverse origins of fibrinolytic enzymes: a comprehensive review. Heliyon 10:e26668. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26668","journal-title":"Heliyon"},{"key":"2438_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/antibiotics12010012","volume":"12","author":"Q Peng","year":"2022","unstructured":"Peng Q, Tang X, Dong W et al (2022) A review of Biofilm formation of Staphylococcus aureus and its regulation mechanism. Antibiot (Basel) 12:12. https:\/\/doi.org\/10.3390\/antibiotics12010012","journal-title":"Antibiot (Basel)"},{"key":"2438_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nrmicro2298","volume":"8","author":"O Tenaillon","year":"2010","unstructured":"Tenaillon O, Skurnik D, Picard B, Denamur E (2010) The population genetics of commensal Escherichia coli. Nat Rev Microbiol 8:207\u2013217. https:\/\/doi.org\/10.1038\/nrmicro2298","journal-title":"Nat Rev Microbiol"},{"key":"2438_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4239\/wjd.v8.i4.135","volume":"8","author":"L Giurato","year":"2017","unstructured":"Giurato L, Meloni M, Izzo V, Uccioli L (2017) Osteomyelitis in diabetic foot: a comprehensive overview. World J Diabetes 8:135\u2013142. https:\/\/doi.org\/10.4239\/wjd.v8.i4.135","journal-title":"World J Diabetes"},{"key":"2438_CR20","doi-asserted-by":"publisher","first-page":"e1010693","DOI":"10.1371\/journal.ppat.1010693","volume":"18","author":"X Huang","year":"2022","unstructured":"Huang X, Li X, An H et al (2022) Capsule type defines the capability of Klebsiella pneumoniae in evading Kupffer cell capture in the liver. PLoS Pathog 18:e1010693. https:\/\/doi.org\/10.1371\/journal.ppat.1010693","journal-title":"PLoS Pathog"},{"key":"2438_CR21","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3390\/antibiotics12071143","volume":"12","author":"C Saben\u00e7a","year":"2023","unstructured":"Saben\u00e7a C, Costa E, Sousa S et al (2023) Evaluation of the ability to Form Biofilms in KPC-Producing and ESBL-Producing Klebsiella pneumoniae isolated from clinical samples. Antibiot (Basel) 12:1143. https:\/\/doi.org\/10.3390\/antibiotics12071143","journal-title":"Antibiot (Basel)"},{"key":"2438_CR22","doi-asserted-by":"publisher","unstructured":"Schaffer JN, Pearson MM (2015) Proteus mirabilis and urinary tract infections. https:\/\/doi.org\/10.1128\/microbiolspec.UTI-0017-2013. Microbiol Spectr 3:","DOI":"10.1128\/microbiolspec.UTI-0017-2013"},{"key":"2438_CR23","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3389\/fcimb.2020.00414","volume":"10","author":"R Wasfi","year":"2020","unstructured":"Wasfi R, Hamed SM, Amer MA, Fahmy LI (2020) Proteus mirabilis Biofilm: development and therapeutic strategies. Front Cell Infect Microbiol 10:414. https:\/\/doi.org\/10.3389\/fcimb.2020.00414","journal-title":"Front Cell Infect Microbiol"},{"key":"2438_CR24","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.mayocpiqo.2022.04.005","volume":"6","author":"I U\u00e7kay","year":"2022","unstructured":"U\u00e7kay I, Lebowitz D, Kressmann B et al (2022) Pseudomonal Diabetic Foot infections: Vive La Diff\u00e9rence? Mayo Clin Proc Innov Qual Outcomes 6:250\u2013256. https:\/\/doi.org\/10.1016\/j.mayocpiqo.2022.04.005","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"2438_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41392-022-01056-1","volume":"7","author":"S Qin","year":"2022","unstructured":"Qin S, Xiao W, Zhou C et al (2022) Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. Sig Transduct Target Ther 7:199. https:\/\/doi.org\/10.1038\/s41392-022-01056-1","journal-title":"Sig Transduct Target Ther"},{"key":"2438_CR26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1080\/07853890.2016.1231932","volume":"49","author":"P Zhang","year":"2017","unstructured":"Zhang P, Lu J, Jing Y et al (2017) Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis \u2020. Ann Med 49:106\u2013116. https:\/\/doi.org\/10.1080\/07853890.2016.1231932","journal-title":"Ann Med"},{"key":"2438_CR27","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.2337\/dc08-9021","volume":"31","author":"AJM Boulton","year":"2008","unstructured":"Boulton AJM, Armstrong DG, Albert SF et al (2008) Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care 31:1679\u20131685. https:\/\/doi.org\/10.2337\/dc08-9021","journal-title":"Diabetes Care"},{"key":"2438_CR28","doi-asserted-by":"publisher","unstructured":"Monteiro-Soares M, Boyko EJ, Jeffcoate W et al (2020) Diabetic foot ulcer classifications: a critical review. Diabetes Metab Res Rev 36 Suppl 1e3272. https:\/\/doi.org\/10.1002\/dmrr.3272","DOI":"10.1002\/dmrr.3272"},{"key":"2438_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13098-022-00842-9","volume":"14","author":"J Lin","year":"2022","unstructured":"Lin J, Song H, Liang M et al (2022) Advances in the study of OSA and diabetic foot. Diabetol Metab Syndr 14:70. https:\/\/doi.org\/10.1186\/s13098-022-00842-9","journal-title":"Diabetol Metab Syndr"},{"key":"2438_CR30","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1001\/jama.287.19.2570","volume":"287","author":"JA Beckman","year":"2002","unstructured":"Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287:2570\u20132581. https:\/\/doi.org\/10.1001\/jama.287.19.2570","journal-title":"JAMA"},{"key":"2438_CR31","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.1016\/j.jvs.2015.10.003","volume":"63","author":"A Hingorani","year":"2016","unstructured":"Hingorani A, LaMuraglia GM, Henke P et al (2016) The management of diabetic foot: a clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg 63:3S\u201321S. https:\/\/doi.org\/10.1016\/j.jvs.2015.10.003","journal-title":"J Vasc Surg"},{"key":"2438_CR32","doi-asserted-by":"publisher","unstructured":"Conte MS, Bradbury AW, Kolh P et al (2019) Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg 69. https:\/\/doi.org\/10.1016\/j.jvs.2019.02.016.:3S-125S.e40","DOI":"10.1016\/j.jvs.2019.02.016"},{"issue":"Suppl 1","key":"2438_CR33","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/dmrr.2707","volume":"32","author":"FL Game","year":"2016","unstructured":"Game FL, Apelqvist J, Attinger C et al (2016) Effectiveness of interventions to enhance healing of chronic ulcers of the foot in diabetes: a systematic review. Diabetes Metab Res Rev 32(Suppl 1):154\u2013168. https:\/\/doi.org\/10.1002\/dmrr.2707","journal-title":"Diabetes Metab Res Rev"},{"key":"2438_CR34","doi-asserted-by":"publisher","first-page":"e13640","DOI":"10.1111\/eci.13640","volume":"51","author":"S Ministrini","year":"2021","unstructured":"Ministrini S, Andreozzi F, Montecucco F et al (2021) Neutrophil degranulation biomarkers characterize restrictive echocardiographic pattern with diastolic dysfunction in patients with diabetes. Eur J Clin Invest 51:e13640. https:\/\/doi.org\/10.1111\/eci.13640","journal-title":"Eur J Clin Invest"},{"key":"2438_CR35","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.3390\/molecules26164917","volume":"26","author":"SM Aitcheson","year":"2021","unstructured":"Aitcheson SM, Frentiu FD, Hurn SE et al (2021) Skin Wound Healing: normal macrophage function and macrophage dysfunction in Diabetic wounds. Molecules 26:4917. https:\/\/doi.org\/10.3390\/molecules26164917","journal-title":"Molecules"},{"key":"2438_CR36","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s00125-017-4377-1","volume":"60","author":"CM Hull","year":"2017","unstructured":"Hull CM, Peakman M, Tree TIM (2017) Regulatory T cell dysfunction in type 1 diabetes: what\u2019s broken and how can we fix it? Diabetologia 60:1839\u20131850. https:\/\/doi.org\/10.1007\/s00125-017-4377-1","journal-title":"Diabetologia"},{"key":"2438_CR37","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/1753-0407.13372","volume":"15","author":"H Deng","year":"2023","unstructured":"Deng H, Li B, Shen Q et al (2023) Mechanisms of diabetic foot ulceration: a review. J Diabetes 15:299\u2013312. https:\/\/doi.org\/10.1111\/1753-0407.13372","journal-title":"J Diabetes"},{"key":"2438_CR38","doi-asserted-by":"publisher","first-page":"7352","DOI":"10.3390\/molecules27217352","volume":"27","author":"YA Kaabi","year":"2022","unstructured":"Kaabi YA (2022) Potential roles of anti-inflammatory plant-derived bioactive compounds targeting inflammation in Microvascular complications of Diabetes. Molecules 27:7352. https:\/\/doi.org\/10.3390\/molecules27217352","journal-title":"Molecules"},{"key":"2438_CR39","doi-asserted-by":"publisher","first-page":"680","DOI":"10.4239\/wjd.v14.i6.680","volume":"14","author":"AAH Rajab","year":"2023","unstructured":"Rajab AAH, Hegazy WAH (2023) What\u2019s old is new again: insights into diabetic foot microbiome. World J Diabetes 14:680\u2013704. https:\/\/doi.org\/10.4239\/wjd.v14.i6.680","journal-title":"World J Diabetes"},{"key":"2438_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/iai.00509-23","author":"BP Darwitz","year":"2024","unstructured":"Darwitz BP, Genito CJ, Thurlow LR (2024) Triple threat: how diabetes results in worsened bacterial infections. Infect Immun. https:\/\/doi.org\/10.1128\/iai.00509-23. e00509-23","journal-title":"Infect Immun"},{"key":"2438_CR41","doi-asserted-by":"publisher","first-page":"747618","DOI":"10.3389\/fmicb.2021.747618","volume":"12","author":"C Pouget","year":"2021","unstructured":"Pouget C, Dunyach-Remy C, Pantel A et al (2021) Alternative approaches for the Management of Diabetic Foot Ulcers. Front Microbiol 12:747618. https:\/\/doi.org\/10.3389\/fmicb.2021.747618","journal-title":"Front Microbiol"},{"key":"2438_CR42","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4239\/wjd.v8.i4.135","volume":"8","author":"L Giurato","year":"2017","unstructured":"Giurato L, Meloni M, Izzo V, Uccioli L (2017) Osteomyelitis in diabetic foot: a comprehensive overview. WJD 8:135. https:\/\/doi.org\/10.4239\/wjd.v8.i4.135","journal-title":"WJD"},{"key":"2438_CR43","doi-asserted-by":"publisher","first-page":"827","DOI":"10.4239\/wjd.v12.i6.827","volume":"12","author":"DO Soyoye","year":"2021","unstructured":"Soyoye DO, Abiodun OO, Ikem RT et al (2021) Diabetes and peripheral artery disease: a review. WJD 12:827\u2013838. https:\/\/doi.org\/10.4239\/wjd.v12.i6.827","journal-title":"WJD"},{"key":"2438_CR44","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3390\/antibiotics10101241","volume":"10","author":"G Boschetti","year":"2021","unstructured":"Boschetti G, Sgarabotto D, Meloni M et al (2021) Antimicrobial resistance patterns in Diabetic Foot infections, an epidemiological study in Northeastern Italy. Antibiotics 10:1241. https:\/\/doi.org\/10.3390\/antibiotics10101241","journal-title":"Antibiotics"},{"key":"2438_CR45","doi-asserted-by":"publisher","first-page":"961","DOI":"10.4239\/wjd.v6.i7.961","volume":"6","author":"T Thiruvoipati","year":"2015","unstructured":"Thiruvoipati T (2015) Peripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomes. WJD 6:961. https:\/\/doi.org\/10.4239\/wjd.v6.i7.961","journal-title":"WJD"},{"key":"2438_CR46","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1128\/CMR.14.2.244-269.2001","volume":"14","author":"PG Bowler","year":"2001","unstructured":"Bowler PG, Duerden BI, Armstrong DG (2001) Wound Microbiology and Associated approaches to Wound Management. Clin Microbiol Rev 14:244\u2013269. https:\/\/doi.org\/10.1128\/CMR.14.2.244-269.2001","journal-title":"Clin Microbiol Rev"},{"key":"2438_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/db20182-1","volume":"2018","author":"A Boulton","year":"2018","unstructured":"Boulton A, Armstrong D, Krisner R et al (2018) Diagnosis and management of Diabetic Foot complications. Compendia 2018:1\u201320. https:\/\/doi.org\/10.2337\/db20182-1","journal-title":"Compendia"},{"key":"2438_CR48","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.2337\/dc12-2108","volume":"36","author":"E Aslangul","year":"2013","unstructured":"Aslangul E, M\u2019Bemba J, Caillat-Vigneron N et al (2013) Diagnosing Diabetic Foot osteomyelitis in patients without signs of Soft tissue infection by coupling hybrid 67Ga SPECT\/CT with Bedside Percutaneous Bone puncture. Diabetes Care 36:2203\u20132210. https:\/\/doi.org\/10.2337\/dc12-2108","journal-title":"Diabetes Care"},{"key":"2438_CR49","doi-asserted-by":"publisher","unstructured":"Meloni M, Bellizzi E, Andreadi A et al (2024) Diabetic Foot osteomyelitis in patients with and without peripheral arterial disease: two different diseases? Int J Low Extrem Wounds 15347346241264383. https:\/\/doi.org\/10.1177\/15347346241264383","DOI":"10.1177\/15347346241264383"},{"key":"2438_CR50","unstructured":"Dobaria DG, Cohen HL (2023) Osteomyelitis Imaging. StatPearls [Internet]. StatPearls Publishing"},{"key":"2438_CR51","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1302\/2058-5241.1.000017","volume":"1","author":"M Panteli","year":"2016","unstructured":"Panteli M, Giannoudis PV (2016) Chronic osteomyelitis: what the surgeon needs to know. EFORT Open Reviews 1:128\u2013135. https:\/\/doi.org\/10.1302\/2058-5241.1.000017","journal-title":"EFORT Open Reviews"},{"issue":"Suppl 1","key":"2438_CR52","doi-asserted-by":"publisher","first-page":"e3280","DOI":"10.1002\/dmrr.3280","volume":"36","author":"BA Lipsky","year":"2020","unstructured":"Lipsky BA, Senneville \u00c9, Abbas ZG et al (2020) Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev 36(Suppl 1):e3280. https:\/\/doi.org\/10.1002\/dmrr.3280","journal-title":"Diabetes Metab Res Rev"},{"key":"2438_CR53","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s11908-009-0053-z","volume":"11","author":"SB Nelson","year":"2009","unstructured":"Nelson SB (2009) Management of diabetic foot infections in an era of increasing microbial resistance. Curr Infect Dis Rep 11:375\u2013382. https:\/\/doi.org\/10.1007\/s11908-009-0053-z","journal-title":"Curr Infect Dis Rep"},{"key":"2438_CR54","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/j.1553-2712.1998.tb02465.x","volume":"5","author":"JV Quinn","year":"1998","unstructured":"Quinn JV, Wells GA (1998) An Assessment of clinical wound evaluation scales. Acad Emerg Med 5:583\u2013586. https:\/\/doi.org\/10.1111\/j.1553-2712.1998.tb02465.x","journal-title":"Acad Emerg Med"},{"key":"2438_CR55","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/dmrr.2246","volume":"28","author":"FL Game","year":"2012","unstructured":"Game FL, Hinchliffe RJ, Apelqvist J et al (2012) A systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metabolism Res 28:119\u2013141. https:\/\/doi.org\/10.1002\/dmrr.2246","journal-title":"Diabetes Metabolism Res"},{"key":"2438_CR56","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1093\/cid\/cis346","volume":"54","author":"BA Lipsky","year":"2012","unstructured":"Lipsky BA, Berendt AR, Cornia PB et al (2012) 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 54:e132\u2013173. https:\/\/doi.org\/10.1093\/cid\/cis346","journal-title":"Clin Infect Dis"},{"key":"2438_CR57","unstructured":"Guidelines (2023) update In: IWGDF Guidelines. https:\/\/iwgdfguidelines.org\/guidelines-2023\/. Accessed 23 Nov 2024"},{"key":"2438_CR58","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3390\/life12071054","volume":"12","author":"MS Baig","year":"2022","unstructured":"Baig MS, Banu A, Zehravi M et al (2022) An overview of Diabetic Foot Ulcers and Associated problems with special emphasis on treatments with antimicrobials. Life (Basel) 12:1054. https:\/\/doi.org\/10.3390\/life12071054","journal-title":"Life (Basel)"},{"key":"2438_CR59","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.3390\/pharmaceutics14081563","volume":"14","author":"D Zapata","year":"2022","unstructured":"Zapata D, Higgs J, Wittholt H et al (2022) Nanotechnology in the diagnosis and treatment of Osteomyelitis. Pharmaceutics 14:1563. https:\/\/doi.org\/10.3390\/pharmaceutics14081563","journal-title":"Pharmaceutics"},{"issue":"Suppl 1","key":"2438_CR60","doi-asserted-by":"publisher","first-page":"e3270","DOI":"10.1002\/dmrr.3270","volume":"36","author":"JJ van Netten","year":"2020","unstructured":"van Netten JJ, Raspovic A, Lavery LA et al (2020) Prevention of foot ulcers in the at-risk patient with diabetes: a systematic review. Diabetes Metab Res Rev 36(Suppl 1):e3270. https:\/\/doi.org\/10.1002\/dmrr.3270","journal-title":"Diabetes Metab Res Rev"},{"issue":"Suppl 1","key":"2438_CR61","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/dmrr.2739","volume":"32","author":"BA Lipsky","year":"2016","unstructured":"Lipsky BA (2016) Diabetic foot infections: current treatment and delaying the post-antibiotic era. Diabetes Metab Res Rev 32(Suppl 1):246\u2013253. https:\/\/doi.org\/10.1002\/dmrr.2739","journal-title":"Diabetes Metab Res Rev"},{"key":"2438_CR62","doi-asserted-by":"publisher","first-page":"100686","DOI":"10.1016\/j.lanepe.2023.100686","volume":"32","author":"D Dardari","year":"2023","unstructured":"Dardari D, Franc S, Charpentier G et al (2023) Hospital stays and costs of telemedical monitoring versus standard follow-up for diabetic foot ulcer: an open-label randomised controlled study. Lancet Reg Health Eur 32:100686. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100686","journal-title":"Lancet Reg Health Eur"},{"key":"2438_CR63","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1524-475X.2007.00321.x","volume":"16","author":"GA James","year":"2008","unstructured":"James GA, Swogger E, Wolcott R et al (2008) Biofilms in chronic wounds. Wound Repair Regen 16:37\u201344. https:\/\/doi.org\/10.1111\/j.1524-475X.2007.00321.x","journal-title":"Wound Repair Regen"},{"key":"2438_CR64","doi-asserted-by":"publisher","first-page":"8278","DOI":"10.3390\/ijms22158278","volume":"22","author":"AC Afonso","year":"2021","unstructured":"Afonso AC, Oliveira D, Saavedra MJ et al (2021) Biofilms in Diabetic Foot Ulcers: impact, risk factors and control strategies. Int J Mol Sci 22:8278. https:\/\/doi.org\/10.3390\/ijms22158278","journal-title":"Int J Mol Sci"},{"key":"2438_CR65","doi-asserted-by":"publisher","first-page":"e0227973","DOI":"10.1371\/journal.pone.0227973","volume":"15","author":"H Kosiyaporn","year":"2020","unstructured":"Kosiyaporn H, Chanvatik S, Issaramalai T et al (2020) Surveys of knowledge and awareness of antibiotic use and antimicrobial resistance in general population: a systematic review. PLoS ONE 15:e0227973. https:\/\/doi.org\/10.1371\/journal.pone.0227973","journal-title":"PLoS ONE"},{"key":"2438_CR66","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1128\/MMBR.00016-10","volume":"74","author":"J Davies","year":"2010","unstructured":"Davies J, Davies D (2010) Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 74:417\u2013433. https:\/\/doi.org\/10.1128\/MMBR.00016-10","journal-title":"Microbiol Mol Biol Rev"},{"key":"2438_CR67","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1093\/jac\/dku168","volume":"69","author":"M Paul","year":"2014","unstructured":"Paul M, Carmeli Y, Durante-Mangoni E et al (2014) Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 69:2305\u20132309. https:\/\/doi.org\/10.1093\/jac\/dku168","journal-title":"J Antimicrob Chemother"},{"key":"2438_CR68","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12902-022-00957-0","volume":"22","author":"X Yan","year":"2022","unstructured":"Yan X, Song J-F, Zhang L, Li X (2022) Analysis of risk factors for multidrug-resistant organisms in diabetic foot infection. BMC Endocr Disord 22:46. https:\/\/doi.org\/10.1186\/s12902-022-00957-0","journal-title":"BMC Endocr Disord"},{"key":"2438_CR69","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cell.2020.02.056","volume":"181","author":"K Lewis","year":"2020","unstructured":"Lewis K (2020) The Science of Antibiotic Discovery. Cell 181:29\u201345. https:\/\/doi.org\/10.1016\/j.cell.2020.02.056","journal-title":"Cell"},{"key":"2438_CR70","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1086\/510393","volume":"44","author":"TH Dellit","year":"2007","unstructured":"Dellit TH, Owens RC, McGowan JE et al (2007) Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44:159\u2013177. https:\/\/doi.org\/10.1086\/510393","journal-title":"Clin Infect Dis"},{"key":"2438_CR71","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/pathogens11060663","volume":"11","author":"E Gerace","year":"2022","unstructured":"Gerace E, Mancuso G, Midiri A et al (2022) Recent advances in the Use of Molecular methods for the diagnosis of bacterial infections. Pathogens 11:663. https:\/\/doi.org\/10.3390\/pathogens11060663","journal-title":"Pathogens"},{"key":"2438_CR72","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3390\/antibiotics10020209","volume":"10","author":"GD Kaprou","year":"2021","unstructured":"Kaprou GD, Berg\u0161pica I, Alexa EA et al (2021) Rapid Methods for Antimicrobial Resistance Diagnostics. Antibiot (Basel) 10:209. https:\/\/doi.org\/10.3390\/antibiotics10020209","journal-title":"Antibiot (Basel)"},{"key":"2438_CR73","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1128\/CMR.05041-11","volume":"25","author":"PD Tamma","year":"2012","unstructured":"Tamma PD, Cosgrove SE, Maragakis LL (2012) Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev 25:450\u2013470. https:\/\/doi.org\/10.1128\/CMR.05041-11","journal-title":"Clin Microbiol Rev"},{"key":"2438_CR74","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1093\/cid\/civ501","volume":"61","author":"SD Burdette","year":"2015","unstructured":"Burdette SD, Trotman R (2015) Tedizolid: the First once-Daily Oxazolidinone Class Antibiotic. Clin Infect Dis 61:1315\u20131321. https:\/\/doi.org\/10.1093\/cid\/civ501","journal-title":"Clin Infect Dis"},{"key":"2438_CR75","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.2147\/DDDT.S164515","volume":"12","author":"SMR Hashemian","year":"2018","unstructured":"Hashemian SMR, Farhadi T, Ganjparvar M (2018) Linezolid: a review of its properties, function, and use in critical care. Drug Des Devel Ther 12:1759\u20131767. https:\/\/doi.org\/10.2147\/DDDT.S164515","journal-title":"Drug Des Devel Ther"},{"key":"2438_CR76","first-page":"269","volume":"90","author":"WA McGuinness","year":"2017","unstructured":"McGuinness WA, Malachowa N, DeLeo FR (2017) Vancomycin Resistance in Staphylococcus aureus. Yale J Biol Med 90:269\u2013281","journal-title":"Yale J Biol Med"},{"key":"2438_CR77","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jgar.2021.04.013","volume":"25","author":"H Zhang","year":"2021","unstructured":"Zhang H, Zhou W, Wang J, Cai Y (2021) Efficacy and safety of oritavancin for the treatment of acute bacterial skin and skin-structure infections: a systematic review and meta-analysis. J Glob Antimicrob Resist 25:380\u2013389. https:\/\/doi.org\/10.1016\/j.jgar.2021.04.013","journal-title":"J Glob Antimicrob Resist"},{"key":"2438_CR78","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1128\/AAC.04614-14","volume":"59","author":"HS Sader","year":"2015","unstructured":"Sader HS, Flamm RK, Streit JM et al (2015) Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program. Antimicrob Agents Chemother 59:2458\u20132461. https:\/\/doi.org\/10.1128\/AAC.04614-14","journal-title":"Antimicrob Agents Chemother"},{"key":"2438_CR79","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12866-022-02644-5","volume":"22","author":"P Jia","year":"2022","unstructured":"Jia P, Zhu Y, Zhang H et al (2022) In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program. BMC Microbiol 22:234. https:\/\/doi.org\/10.1186\/s12866-022-02644-5","journal-title":"BMC Microbiol"},{"key":"2438_CR80","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/jac\/dkh546","volume":"55","author":"JN Steenbergen","year":"2005","unstructured":"Steenbergen JN, Alder J, Thorne GM, Tally FP (2005) Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 55:283\u2013288. https:\/\/doi.org\/10.1093\/jac\/dkh546","journal-title":"J Antimicrob Chemother"},{"key":"2438_CR81","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/IDR.S6961","volume":"3","author":"A Beiras-Fernandez","year":"2010","unstructured":"Beiras-Fernandez A, Vogt F, Sodian R, Weis F (2010) Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens. Infect Drug Resist 3:95\u2013101. https:\/\/doi.org\/10.2147\/IDR.S6961","journal-title":"Infect Drug Resist"},{"key":"2438_CR82","doi-asserted-by":"publisher","unstructured":"Lan S-H, Lin W-T, Chang S-P et al (2019) Tedizolid Versus Linezolid for the treatment of Acute bacterial skin and skin structure infection: a systematic review and Meta-analysis. Antibiot (Basel) 8137. https:\/\/doi.org\/10.3390\/antibiotics8030137","DOI":"10.3390\/antibiotics8030137"},{"key":"2438_CR83","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3390\/pathogens13030189","volume":"13","author":"V Siciliano","year":"2024","unstructured":"Siciliano V, Sangiorgi F, Del Vecchio P et al (2024) New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides. Pathogens 13:189. https:\/\/doi.org\/10.3390\/pathogens13030189","journal-title":"Pathogens"},{"issue":"Suppl 4","key":"2438_CR84","doi-asserted-by":"publisher","first-page":"iv41","DOI":"10.1093\/jac\/dkq254","volume":"65","author":"GR Corey","year":"2010","unstructured":"Corey GR, Wilcox MH, Talbot GH et al (2010) CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 65(Suppl 4):iv41\u201351. https:\/\/doi.org\/10.1093\/jac\/dkq254","journal-title":"J Antimicrob Chemother"},{"key":"2438_CR85","doi-asserted-by":"publisher","first-page":"792","DOI":"10.2174\/1381612822666151209151719","volume":"22","author":"Q Zia","year":"2016","unstructured":"Zia Q, Azhar A, Amjad Kamal M et al (2016) Super aggregated form of amphotericin B: a novel way to increase its therapeutic index. CPD 22:792\u2013803. https:\/\/doi.org\/10.2174\/1381612822666151209151719","journal-title":"CPD"},{"key":"2438_CR86","doi-asserted-by":"publisher","first-page":"35442","DOI":"10.1021\/acsomega.3c04893","volume":"8","author":"R Ghosh","year":"2023","unstructured":"Ghosh R, De M (2023) Liposome-based antibacterial delivery: an Emergent Approach to combat bacterial infections. ACS Omega 8:35442\u201335451. https:\/\/doi.org\/10.1021\/acsomega.3c04893","journal-title":"ACS Omega"},{"key":"2438_CR87","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/polym3031377","volume":"3","author":"HK Makadia","year":"2011","unstructured":"Makadia HK, Siegel SJ (2011) Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polym (Basel) 3:1377\u20131397. https:\/\/doi.org\/10.3390\/polym3031377","journal-title":"Polym (Basel)"},{"key":"2438_CR88","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.polymer.2008.01.027","volume":"49","author":"TR Hoare","year":"2008","unstructured":"Hoare TR, Kohane DS (2008) Hydrogels in drug delivery: Progress and challenges. Polymer 49:1993\u20132007. https:\/\/doi.org\/10.1016\/j.polymer.2008.01.027","journal-title":"Polymer"},{"key":"2438_CR89","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.addr.2012.04.005","volume":"64","author":"Y-C Kim","year":"2012","unstructured":"Kim Y-C, Park J-H, Prausnitz MR (2012) Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev 64:1547\u20131568. https:\/\/doi.org\/10.1016\/j.addr.2012.04.005","journal-title":"Adv Drug Deliv Rev"},{"key":"2438_CR90","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/j.1365-2672.2012.05253.x","volume":"112","author":"MK Rai","year":"2012","unstructured":"Rai MK, Deshmukh SD, Ingle AP, Gade AK (2012) Silver nanoparticles: the powerful nanoweapon against multidrug-resistant bacteria. J Appl Microbiol 112:841\u2013852. https:\/\/doi.org\/10.1111\/j.1365-2672.2012.05253.x","journal-title":"J Appl Microbiol"},{"key":"2438_CR91","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.addr.2009.03.007","volume":"61","author":"VI Shubayev","year":"2009","unstructured":"Shubayev VI, Pisanic TR, Jin S (2009) Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev 61:467\u2013477. https:\/\/doi.org\/10.1016\/j.addr.2009.03.007","journal-title":"Adv Drug Deliv Rev"},{"key":"2438_CR92","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1007\/s00203-021-02357-9","volume":"203","author":"Y Gupta","year":"2021","unstructured":"Gupta Y, Ghrera AS (2021) Recent advances in gold nanoparticle-based lateral flow immunoassay for the detection of bacterial infection. Arch Microbiol 203:3767\u20133784. https:\/\/doi.org\/10.1007\/s00203-021-02357-9","journal-title":"Arch Microbiol"},{"key":"2438_CR93","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3390\/pharmaceutics12070630","volume":"12","author":"SH Pham","year":"2020","unstructured":"Pham SH, Choi Y, Choi J (2020) Stimuli-Responsive nanomaterials for application in Antitumor Therapy and Drug Delivery. Pharmaceutics 12:630. https:\/\/doi.org\/10.3390\/pharmaceutics12070630","journal-title":"Pharmaceutics"},{"key":"2438_CR94","doi-asserted-by":"publisher","first-page":"9541","DOI":"10.3390\/app11209541","volume":"11","author":"Z Xiang","year":"2021","unstructured":"Xiang Z, Liu M, Song J (2021) Stimuli-Responsive Polymeric nanosystems for Controlled Drug Delivery. Appl Sci 11:9541. https:\/\/doi.org\/10.3390\/app11209541","journal-title":"Appl Sci"},{"key":"2438_CR95","doi-asserted-by":"publisher","first-page":"104707","DOI":"10.1016\/j.meegid.2021.104707","volume":"88","author":"Y-H Ku","year":"2021","unstructured":"Ku Y-H, Yu W-L (2021) Cefoperazone\/sulbactam: New composites against multiresistant gram negative bacteria? Infect Genet Evol 88:104707. https:\/\/doi.org\/10.1016\/j.meegid.2021.104707","journal-title":"Infect Genet Evol"},{"key":"2438_CR96","doi-asserted-by":"publisher","first-page":"e0040523","DOI":"10.1128\/aac.00405-23","volume":"67","author":"TA Almangour","year":"2023","unstructured":"Almangour TA, Ghonem L, Alassiri D et al (2023) Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the treatment of infections caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study. Antimicrob Agents Chemother 67:e0040523. https:\/\/doi.org\/10.1128\/aac.00405-23","journal-title":"Antimicrob Agents Chemother"},{"key":"2438_CR97","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/ja.2014.111","volume":"67","author":"MS Butler","year":"2014","unstructured":"Butler MS, Hansford KA, Blaskovich MAT et al (2014) Glycopeptide antibiotics: back to the future. J Antibiot 67:631\u2013644. https:\/\/doi.org\/10.1038\/ja.2014.111","journal-title":"J Antibiot"},{"key":"2438_CR98","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/jac\/dkh531","volume":"55","author":"BA Lipsky","year":"2005","unstructured":"Lipsky BA, Stoutenburgh U (2005) Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with Vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother 55:240\u2013245. https:\/\/doi.org\/10.1093\/jac\/dkh531","journal-title":"J Antimicrob Chemother"},{"key":"2438_CR99","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/CE.S187499","volume":"14","author":"M Bassetti","year":"2019","unstructured":"Bassetti M, Castaldo N, Carnelutti A et al (2019) Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy. Core Evid 14:31\u201340. https:\/\/doi.org\/10.2147\/CE.S187499","journal-title":"Core Evid"},{"key":"2438_CR100","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s13300-022-01357-2","volume":"14","author":"E Mougakou","year":"2023","unstructured":"Mougakou E, Mastrogianni E, Kyziroglou M, Tziomalos K (2023) The role of Novel antibiotics in the Management of Diabetic Foot infection. Diabetes Ther 14:251\u2013263. https:\/\/doi.org\/10.1007\/s13300-022-01357-2","journal-title":"Diabetes Ther"},{"key":"2438_CR101","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s40121-023-00773-6","volume":"12","author":"KS Kaye","year":"2023","unstructured":"Kaye KS, Naas T, Pogue JM, Rossolini GM (2023) Cefiderocol, a Siderophore Cephalosporin, as a treatment option for infections caused by Carbapenem-Resistant Enterobacterales. Infect Dis Ther 12:777\u2013806. https:\/\/doi.org\/10.1007\/s40121-023-00773-6","journal-title":"Infect Dis Ther"},{"key":"2438_CR102","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.1128\/AAC.00634-15","volume":"59","author":"E Sacco","year":"2015","unstructured":"Sacco E, Cortes M, Josseaume N et al (2015) Mutation landscape of acquired cross-resistance to glycopeptide and \u03b2-lactam antibiotics in Enterococcus faecium. Antimicrob Agents Chemother 59:5306\u20135315. https:\/\/doi.org\/10.1128\/AAC.00634-15","journal-title":"Antimicrob Agents Chemother"},{"key":"2438_CR103","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4292\/wjgpt.v8.i3.162","volume":"8","author":"DM Lin","year":"2017","unstructured":"Lin DM, Koskella B, Lin HC (2017) Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther 8:162\u2013173. https:\/\/doi.org\/10.4292\/wjgpt.v8.i3.162","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"2438_CR104","doi-asserted-by":"publisher","first-page":"e000309","DOI":"10.1099\/mgen.0.000309","volume":"5","author":"EL Mangas","year":"2019","unstructured":"Mangas EL, Rubio A, \u00c1lvarez-Mar\u00edn R et al (2019) Pangenome of Acinetobacter baumannii uncovers two groups of genomes, one of them with genes involved in CRISPR\/Cas defence systems associated with the absence of plasmids and exclusive genes for biofilm formation. Microb Genom 5:e000309. https:\/\/doi.org\/10.1099\/mgen.0.000309","journal-title":"Microb Genom"},{"key":"2438_CR105","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s10096-015-2323-z","volume":"34","author":"I Olsen","year":"2015","unstructured":"Olsen I (2015) Biofilm-specific antibiotic tolerance and resistance. Eur J Clin Microbiol Infect Dis 34:877\u2013886. https:\/\/doi.org\/10.1007\/s10096-015-2323-z","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2438_CR106","doi-asserted-by":"publisher","first-page":"7297419","DOI":"10.1155\/2021\/7297419","volume":"2021","author":"TV Velikova","year":"2021","unstructured":"Velikova TV, Kabakchieva PP, Assyov YS, Georgiev T\u0410 (2021) Targeting Inflammatory cytokines to improve type 2 Diabetes Control. Biomed Res Int 2021:7297419. https:\/\/doi.org\/10.1155\/2021\/7297419","journal-title":"Biomed Res Int"},{"key":"2438_CR107","doi-asserted-by":"publisher","first-page":"1216321","DOI":"10.3389\/fimmu.2023.1216321","volume":"14","author":"S Nirenjen","year":"2023","unstructured":"Nirenjen S, Narayanan J, Tamilanban T et al (2023) Exploring the contribution of pro-inflammatory cytokines to impaired wound healing in diabetes. Front Immunol 14:1216321. https:\/\/doi.org\/10.3389\/fimmu.2023.1216321","journal-title":"Front Immunol"},{"key":"2438_CR108","doi-asserted-by":"publisher","first-page":"1135541","DOI":"10.3389\/fmed.2023.1135541","volume":"10","author":"H Qadri","year":"2023","unstructured":"Qadri H, Shah AH, Alkhanani M et al (2023) Immunotherapies against human bacterial and fungal infectious diseases: a review. Front Med (Lausanne) 10:1135541. https:\/\/doi.org\/10.3389\/fmed.2023.1135541","journal-title":"Front Med (Lausanne)"},{"key":"2438_CR109","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41435-021-00129-5","volume":"22","author":"RB Panwar","year":"2021","unstructured":"Panwar RB, Sequeira RP, Clarke TB (2021) Microbiota-mediated protection against antibiotic-resistant pathogens. Genes Immun 22:255\u2013267. https:\/\/doi.org\/10.1038\/s41435-021-00129-5","journal-title":"Genes Immun"},{"key":"2438_CR110","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41586-022-05019-y","volume":"608","author":"R Shukla","year":"2022","unstructured":"Shukla R, Lavore F, Maity S et al (2022) Teixobactin kills bacteria by a two-pronged attack on the cell envelope. Nature 608:390\u2013396. https:\/\/doi.org\/10.1038\/s41586-022-05019-y","journal-title":"Nature"},{"key":"2438_CR111","doi-asserted-by":"publisher","first-page":"21391","DOI":"10.1021\/acsomega.3c02239","volume":"8","author":"L Kumar","year":"2023","unstructured":"Kumar L, Bisen M, Harjai K et al (2023) Advances in nanotechnology for Biofilm Inhibition. ACS Omega 8:21391\u201321409. https:\/\/doi.org\/10.1021\/acsomega.3c02239","journal-title":"ACS Omega"},{"key":"2438_CR112","doi-asserted-by":"publisher","first-page":"10757","DOI":"10.1021\/acsomega.3c00312","volume":"8","author":"G Dhanda","year":"2023","unstructured":"Dhanda G, Acharya Y, Haldar J (2023) Antibiotic adjuvants: a Versatile Approach to Combat Antibiotic Resistance. ACS Omega 8:10757\u201310783. https:\/\/doi.org\/10.1021\/acsomega.3c00312","journal-title":"ACS Omega"},{"key":"2438_CR113","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1057\/s41599-020-0478-4","volume":"6","author":"C Brives","year":"2020","unstructured":"Brives C, Pourraz J (2020) Phage therapy as a potential solution in the fight against AMR: obstacles and possible futures. Palgrave Commun 6:100. https:\/\/doi.org\/10.1057\/s41599-020-0478-4","journal-title":"Palgrave Commun"},{"key":"2438_CR114","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1021\/acsinfecdis.2c00649","volume":"9","author":"A Mayorga-Ramos","year":"2023","unstructured":"Mayorga-Ramos A, Z\u00fa\u00f1iga-Miranda J, Carrera-Pacheco SE et al (2023) CRISPR-Cas-based antimicrobials: design, challenges, and bacterial mechanisms of resistance. ACS Infect Dis 9:1283\u20131302. https:\/\/doi.org\/10.1021\/acsinfecdis.2c00649","journal-title":"ACS Infect Dis"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-024-02438-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-024-02438-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-024-02438-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T02:52:27Z","timestamp":1740797547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-024-02438-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":114,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["2438"],"URL":"https:\/\/doi.org\/10.1007\/s00592-024-02438-3","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"7 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No ethical approval was taken as it is a review article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}